Detail
Článek
Článek online
FT
Medvik - BMČ
  • Je něco špatně v tomto záznamu ?

Ixazomib-Thalidomide-Dexamethasone for induction therapy followed by Ixazomib maintenance treatment in patients with relapsed/refractory multiple myeloma

H. Ludwig, W. Poenisch, S. Knop, A. Egle, M. Schreder, D. Lechner, R. Hajek, E. Gunsilius, KJ. Krenosz, A. Petzer, K. Weisel, D. Niederwieser, H. Einsele, W. Willenbacher, T. Melchardt, R. Greil, N. Zojer,

. 2019 ; 121 (9) : 751-757. [pub] 20190927

Jazyk angličtina Země Velká Británie

Typ dokumentu klinické zkoušky, časopisecké články, práce podpořená grantem

Perzistentní odkaz   https://www.medvik.cz/link/bmc20023608
E-zdroje Online Plný text

NLK Free Medical Journals od 1947 do Před 1 rokem
Freely Accessible Journals od 1947 do Před 1 rokem
PubMed Central od 1947 do Před 1 rokem
Europe PubMed Central od 1947 do Před 1 rokem
ProQuest Central od 2000-01-01 do Před 1 rokem
Open Access Digital Library od 1947-01-01
Open Access Digital Library od 1999-01-01
Nursing & Allied Health Database (ProQuest) od 2000-01-01 do Před 1 rokem
Health & Medicine (ProQuest) od 2000-01-01 do Před 1 rokem
Public Health Database (ProQuest) od 2000-01-01 do Před 1 rokem

Odkazy

PubMed 31558804
DOI 10.1038/s41416-019-0581-8
Knihovny.cz E-zdroje

BACKGROUND: Ixazomib-revlimid-dexamethason showed significant activity in relapsed/refractory multiple myeloma (RRMM). Here, we evaluate ixazomib in combination with thalidomide and dexamethasone for induction treatment followed by ixazomib maintenance therapy in RRMM patients. METHODS: Ninety patients have been included. Ixazomib-thalidomide-dexamethasone (4 mg, day 1, 8, 15; 100 mg daily; and 40 mg weekly) was scheduled for eight cycles followed by maintenance with ixazomib for one year. RESULTS: The overall response rate was 51.1%, 23.3% achieved CR or VGPR and 10% MR resulting in a clinical benefit rate of 61.1%. In patients completing ≥2 cycles, the rates were 60.5%, 27.6% and 68.4%, respectively. Median progression-free survival (PFS) was 8.5 months in all, and 9.4 months in those completing ≥2 cycles. Response rates, PFS and overall survival (OS) were similar in patients with and without t(4;14) and/or del(17p), but PFS and OS was significantly shorter in patients with gain of 1q21. Multivariate regression analysis revealed gain of 1q21 as the most important factor associated with OS. Ixazomib maintenance resulted in an upgrade in the depth of response in 12.4% of patients. Grade 3/4 toxicities were relatively rare. CONCLUSIONS: Ixazomib-thalidomide-dexamethasone followed by ixazomib maintenance therapy is active and well tolerated in patients with RRMM. TRIAL REGISTRATION NUMBER: NCT02410694.

Citace poskytuje Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc20023608
003      
CZ-PrNML
005      
20201214130552.0
007      
ta
008      
201125s2019 xxk f 000 0|eng||
009      
AR
024    7_
$a 10.1038/s41416-019-0581-8 $2 doi
035    __
$a (PubMed)31558804
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a xxk
100    1_
$a Ludwig, Heinz $u Wilhelminen Cancer Research Institute, Department of Medicine I, Center for Oncology and Hematology, Wilhelminenspital, Vienna, Austria. heinz.ludwig@wienkav.at.
245    10
$a Ixazomib-Thalidomide-Dexamethasone for induction therapy followed by Ixazomib maintenance treatment in patients with relapsed/refractory multiple myeloma / $c H. Ludwig, W. Poenisch, S. Knop, A. Egle, M. Schreder, D. Lechner, R. Hajek, E. Gunsilius, KJ. Krenosz, A. Petzer, K. Weisel, D. Niederwieser, H. Einsele, W. Willenbacher, T. Melchardt, R. Greil, N. Zojer,
520    9_
$a BACKGROUND: Ixazomib-revlimid-dexamethason showed significant activity in relapsed/refractory multiple myeloma (RRMM). Here, we evaluate ixazomib in combination with thalidomide and dexamethasone for induction treatment followed by ixazomib maintenance therapy in RRMM patients. METHODS: Ninety patients have been included. Ixazomib-thalidomide-dexamethasone (4 mg, day 1, 8, 15; 100 mg daily; and 40 mg weekly) was scheduled for eight cycles followed by maintenance with ixazomib for one year. RESULTS: The overall response rate was 51.1%, 23.3% achieved CR or VGPR and 10% MR resulting in a clinical benefit rate of 61.1%. In patients completing ≥2 cycles, the rates were 60.5%, 27.6% and 68.4%, respectively. Median progression-free survival (PFS) was 8.5 months in all, and 9.4 months in those completing ≥2 cycles. Response rates, PFS and overall survival (OS) were similar in patients with and without t(4;14) and/or del(17p), but PFS and OS was significantly shorter in patients with gain of 1q21. Multivariate regression analysis revealed gain of 1q21 as the most important factor associated with OS. Ixazomib maintenance resulted in an upgrade in the depth of response in 12.4% of patients. Grade 3/4 toxicities were relatively rare. CONCLUSIONS: Ixazomib-thalidomide-dexamethasone followed by ixazomib maintenance therapy is active and well tolerated in patients with RRMM. TRIAL REGISTRATION NUMBER: NCT02410694.
650    _2
$a dospělí $7 D000328
650    _2
$a senioři $7 D000368
650    _2
$a senioři nad 80 let $7 D000369
650    _2
$a protokoly protinádorové kombinované chemoterapie $x škodlivé účinky $x terapeutické užití $7 D000971
650    _2
$a sloučeniny boru $x aplikace a dávkování $x škodlivé účinky $7 D001896
650    _2
$a dexamethason $x aplikace a dávkování $x škodlivé účinky $7 D003907
650    _2
$a ženské pohlaví $7 D005260
650    _2
$a glycin $x aplikace a dávkování $x škodlivé účinky $x analogy a deriváty $7 D005998
650    _2
$a lidé $7 D006801
650    _2
$a indukční chemoterapie $7 D060828
650    _2
$a udržovací chemoterapie $7 D060046
650    _2
$a mužské pohlaví $7 D008297
650    _2
$a lidé středního věku $7 D008875
650    _2
$a mnohočetný myelom $x farmakoterapie $7 D009101
650    _2
$a doba přežití bez progrese choroby $7 D000077982
650    _2
$a míra přežití $7 D015996
650    _2
$a thalidomid $x aplikace a dávkování $x škodlivé účinky $7 D013792
655    _2
$a klinické zkoušky $7 D016430
655    _2
$a časopisecké články $7 D016428
655    _2
$a práce podpořená grantem $7 D013485
700    1_
$a Poenisch, Wolfram $u Department of Hematology, University of Leipzig, Leipzig, Germany.
700    1_
$a Knop, Stefan $u Division of Hematology and Medical Oncology, Department of Internal Medicine II, Wuerzburg University Medical Center, Wuerzburg, Germany.
700    1_
$a Egle, Alexander $u Department of Internal Medicine III with Haematology, Medical Oncology, Hemostaseology, Infectiology and Rheumatology, Oncologic Center, Salzburg Cancer Research Institute-Laboratory for Immunological and Molecular Cancer Research (SCRI-LIMCR), Paracelsus Medical University, Salzburg, Cancer Cluster Salzburg, Austria.
700    1_
$a Schreder, Martin $u Department of Medicine I, Center for Oncology and Hematology, Wilhelminenspital, Vienna, Austria.
700    1_
$a Lechner, Daniel $u Department of Medicine I-Hematology with Stem Cell Transplantation, Hemostaseology and Medical Oncology, Ordensklinikum Linz Elisabethinen, Linz, Austria.
700    1_
$a Hajek, Roman $u Fakultní Nemocnice Ostrava, Ostrava, Czech Republic.
700    1_
$a Gunsilius, Eberhard $u Department of Internal Medicine V, Hematology and Oncology, Medical University Innsbruck, Innsbruck, Austria.
700    1_
$a Krenosz, Karl Jochen $u Department of Internal Medicine 3, Kepler Universitaetsklinikum GmbH, Med Campus III, Linz, Austria.
700    1_
$a Petzer, Andreas $u Department of Internal Medicine I, Ordensklinikum Linz-Barmherzige Schwestern, Linz, Austria.
700    1_
$a Weisel, Katja $u University Medical Center of Hamburg-Eppendorf, Hamburg, Germany and University of Tuebingen, Tuebingen, Germany.
700    1_
$a Niederwieser, Dietger $u Department of Hematology, University of Leipzig, Leipzig, Germany.
700    1_
$a Einsele, Hermann $u Division of Hematology and Medical Oncology, Department of Internal Medicine II, Wuerzburg University Medical Center, Wuerzburg, Germany.
700    1_
$a Willenbacher, Wolfgang $u Department of Internal Medicine V, Hematology and Oncology, Medical University Innsbruck, Innsbruck, Austria. Oncotyrol, Center for personalized Cancer Medicine, Innsbruck, Austria.
700    1_
$a Melchardt, Thomas $u Department of Internal Medicine III with Haematology, Medical Oncology, Hemostaseology, Infectiology and Rheumatology, Oncologic Center, Salzburg Cancer Research Institute-Laboratory for Immunological and Molecular Cancer Research (SCRI-LIMCR), Paracelsus Medical University, Salzburg, Cancer Cluster Salzburg, Austria.
700    1_
$a Greil, Richard $u Department of Internal Medicine III with Haematology, Medical Oncology, Hemostaseology, Infectiology and Rheumatology, Oncologic Center, Salzburg Cancer Research Institute-Laboratory for Immunological and Molecular Cancer Research (SCRI-LIMCR), Paracelsus Medical University, Salzburg, Cancer Cluster Salzburg, Austria.
700    1_
$a Zojer, Niklas $u Department of Medicine I, Center for Oncology and Hematology, Wilhelminenspital, Vienna, Austria.
773    0_
$w MED00009369 $t British journal of cancer $x 1532-1827 $g Roč. 121, č. 9 (2019), s. 751-757
856    41
$u https://pubmed.ncbi.nlm.nih.gov/31558804 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y a $z 0
990    __
$a 20201125 $b ABA008
991    __
$a 20201214130550 $b ABA008
999    __
$a ok $b bmc $g 1595927 $s 1114284
BAS    __
$a 3
BAS    __
$a PreBMC
BMC    __
$a 2019 $b 121 $c 9 $d 751-757 $e 20190927 $i 1532-1827 $m British journal of cancer $n Br J Cancer $x MED00009369
LZP    __
$a Pubmed-20201125

Najít záznam

Citační ukazatele

Možnosti archivace